67500-19-0

Basic information

• Product Name: Ethanone, 1-(5-amino-2-fluorophenyl)- (9CI)
• Synonyms: Ethanone, 1-(5-amino-2-fluorophenyl)- (9CI);1-(5-AMINO-2-FLUOROPHENYL)ETHANONE;Ethanone, 1-(5-aMino-2-fluorophenyl)-;1-(5-Amino-2-fluorophenyl)ethan-1-one, 3-Acetyl-4-fluoroaniline;5'-Amino-2'-fluoroecetophenone;1-(5-Amino-2-fluorophenyl)
• CAS NO: 67500-19-0
• Molecular Formula: C₈H₈FNO
• Molecular Weight: 153.1536232
• Product Categories: ACETYLGROUP;Fluorine series
• Mol File: 67500-19-0.mol
• Article Data: 10

Chemical Properties

• Melting Point: 76-77 °C(Solv: cyclohexane (110-82-7))
• Boiling Point: 295.8±20.0 °C(Predicted)
• Appearance: /
• Density: 1.201±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 3.47±0.10(Predicted)
• CAS DataBase Reference: Ethanone, 1-(5-amino-2-fluorophenyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1-(5-amino-2-fluorophenyl)- (9CI)(67500-19-0)
• EPA Substance Registry System: Ethanone, 1-(5-amino-2-fluorophenyl)- (9CI)(67500-19-0)

Safety Data

• Hazardous Substances Data: 67500-19-0(Hazardous Substances Data)

Usage

Description

Ethanone, 1-(5-amino-2-fluorophenyl)(9CI) is an organic compound that features a fluorophenyl group attached to an ethanone moiety. This unique structure endows it with specific chemical properties that make it a valuable intermediate in the synthesis of various pharmaceutical compounds.

Uses

Used in Pharmaceutical Industry:
Ethanone, 1-(5-amino-2-fluorophenyl)(9CI) is used as a key reactant for the synthesis of 9-arylpurines, which represent a novel class of antiviral agents. These compounds have demonstrated inhibitory effects against Enteroviruses, a broad genus of viruses responsible for a range of illnesses, including respiratory infections, meningitis, and heart diseases. The development of effective inhibitors is crucial for the treatment and prevention of Enterovirus-related diseases, making the use of this compound in pharmaceutical applications highly significant.

Upstream product

• 79110-05-7 1-(2-fluoro-5-nitrophenyl)ethanone 
• 99-03-6 1-(3-aminophenyl)ethanone 
• 445-27-2 2'-Fluoroacetophenone 
• 400-93-1 3-nitro-4-fluoroacetophenone 

Downstream Products

• 1200437-82-6 N₄-(3'-acetyl-4'-fluorophenyl)-6-chloropyrimidine-4,5-diamine 
• 1286770-55-5 N-[3-[(5R)-3-amino-5,6-dihydro-2,5-dimethyl-1,1-dioxido-2H-1,2,4-thiadiazin-5-yl]-4-fluorophenyl]-5-fluoro-2-pyridinecarboxamide 
• 1312682-32-8 C₃₁H₂₇Cl₂FN₂O₃ 
• 1312682-29-3 C₃₁H₂₈ClFN₂O₄ 
• 1312682-22-6 C₁₇H₁₈FN₅OS 
• 1312682-12-4 C₂₄H₂₄FNO₃ 
• 1248501-48-5 C₁₆H₁₈FN₅O₂S 

Relevant articles and documents

COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS

The present invention relates to compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein X, Y, Z, Q, W, m, u, ring (A), R2, R3, R4, R5 and R6, are as defined in the specification and claims. The present invention provides a pharmaceutical composition containing the compounds of Formula (I) and a therapeutic method of treating and/or preventing Downs syndrome, β-amyloid angiopathy, disorders associated with cognitive impairment, Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegenerative diseases, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, Alzheimer's disease and/or Down syndrome, age-related macular degeneration (AMD), glaucoma, olfactory function impairment, traumatic brain injury, progressive muscle diseases, Type II diabetes mellitus and cardiovascular diseases (stroke).

4-AMINO-1,3-THIAZINE OR OXAZINE DERIVATIVE

The present invention provide a medicament for treating the diseases induced by production, secretion or deposition of amyloid-β proteins, for example, a compound of the following formula (I) wherein R1, R2a, R2b, R3a

9-Arylpurines as a novel class of enterovirus inhibitors

Here we report on a novel class of enterovirus inhibitors that can be structurally described as 9-arylpurines. These compounds elicit activity against a variety of enteroviruses in the low μM range including Coxsackie virus A16, A21, A24, Coxsackie virus B3, and echovirus 9. Structure-activity relationship (SAR) studies indicate that a chlorine or bromine atomis required at position 6 of the purine ring for antiviral activity. The most selective compounds in this series inhibited Coxsackie virus B3 replication in a dose-dependent manner with EC50 values around 5-8 μM. Notoxicity on different cell lineswas observed at concentrations up to 250 μM. Moreover, no cross-resistance to TBZE-029 and TTP-8307 CVB3 resistant strains was detected.